Johan Skog,
Chief Scientific Officer,
Exosome Diagnostics Inc
Dr. Skog currently serves as chief scientific officer of Exosome Diagnostics where he is leading the research and development efforts for biofluid diagnostics using exosomes in diseases such as cancer, metabolic and neurodegenerative diseases. He is the primary inventor of Exosome Diagnostics' core technology and, in particular, blood-based genetic diagnostics of cancer. Dr. Skog made the discovery that tumor-shed exosomes (microvesicles) contain genetic information of the tumor. He showed that these microvesicles serve to deliver messages to other cells inducing changes favorable to the proliferation of cancer cells. He demonstrated that these tumor exosomes are released into the bloodstream and that they can be isolated and studied for genetic mutations (Skog et al. Nature Cell Biology 2008; 10: 1470-1476). Prior to the start of the company Exosome Diagnostics, Dr. Skog was working at Massachusetts General Hospital/Harvard Medical School where he was studying the role of tumor stem cells in gliomas and later tumor derived exosomes, including their content of RNA biomarkers and transposable elements such as endogenous retroviruses. He also showed that gene therapy vectors can be incorporated into microvesicles and be used as a “stealth” vector with changed tropisms (Maguire et al. Molecular Therapy 2012 Feb 7). Dr. Skog received his PhD at the Department of Virology, Umea University, Sweden, working on novel gene therapy vectors for treatment of gliomas.
|
|
|